News | Structural Heart | March 31, 2023

Abbott Receives FDA Approval for Epic Max Tissue Valve to Treat Aortic Valve Disease

The new valve is designed to preserve and facilitate future patient options for lifetime management of their heart valve disease

The new valve is designed to preserve and facilitate future patient options for lifetime management of their heart valve disease

March 31, 2023 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the company's Epic Max stented tissue valve to treat people with aortic regurgitation or stenosis. This device is the latest addition to Abbott's Epic surgical valve platform which has a decades-long history of safety and strong clinical outcomes, with an optimized design to further improve valve blood flow.

When the aortic valve doesn't close properly (aortic regurgitation) or fails to open fully (aortic stenosis), the heart doesn’t pump blood efficiently and blood flow to the body is reduced. If left untreated, aortic valve disease can lead to heart failure, stroke, blood clots or death. Diseased or damaged heart valves that can't be repaired may be surgically replaced with either mechanical or bioprosthetic (tissue) valves in an open-heart surgical procedure. Bioprosthetic valves like Epic Max are recommended for patients requiring valve replacement who aren't suitable for taking blood-thinning medication.

Epic Max is designed to achieve excellent hemodynamics, or blood flow, and its low-profile frame facilitates potential future transcatheter interventions for patients. This new valve is built on the Epic surgical valve platform, leveraging its long-term performance and durability.  

"The aortic valve is one of the heart valves most commonly impacted by cardiovascular disease, frequently requiring replacement," said Joseph E. Bavaria, M.D., cardiovascular surgery, University of Pennsylvania, "Abbott's Epic Max design optimizes blood flow for patients and has a low profile that makes future cardiac interventions, if necessary, easier."

"With Epic Max, we're accomplishing two important things: First and foremost, we're improving heart valve hemodynamics, which is the purpose of the procedure. Secondly, we're preserving options and ability for patient lifetime disease management, an ever more critical point of consideration in device therapy selection," said Michael Dale, senior vice president of Abbott's structural heart business.

For more information: https://abbo.tt/EpicMaxISI


Related Content

News | Structural Heart

May 24, 2023 — Medtronic announced two-year results of their Harmony Transcatheter Pulmonary Valve (TPV) System, which ...

Home May 24, 2023
Home
News | Structural Heart

May 19, 2023 — Abbott announced late-breaking data that add to the body of clinical evidence supporting the benefits of ...

Home May 19, 2023
Home
News | Structural Heart

May 17, 2023 — Edwards Lifesciences announced that new data from the Benchmark Registry in Europe demonstrated the ...

Home May 17, 2023
Home
News | Structural Heart

March 16, 2023 — Cardiologists at the UW Medicine Heart Institute recently performed a first-in-the-world procedure ...

Home May 16, 2023
Home
News | Structural Heart

May 16, 2023 — Henry Ford Health Interventional cardiologists William O’Neill, M.D., and Khaldoon Alaswad, M.D., took a ...

Home May 16, 2023
Home
News | Structural Heart

May 15, 2023 — The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature ...

Home May 15, 2023
Home
News | Structural Heart

March 14, 2023 — The Society of Thoracic Surgeons (STS) has developed and launched a new risk calculator to estimate the ...

Home March 14, 2023
Home
News | Structural Heart

March 5, 2023 — In patients with heart failure and a poorly functioning heart valve, a minimally invasive procedure ...

Home March 05, 2023
Home
News | Structural Heart

March 4, 2023 — Abbott announced late-breaking data for the TriClip transcatheter edge-to-edge repair (TEER) system, a ...

Home March 04, 2023
Home
News | Structural Heart

February 6, 2023 — University of Virginia researchers and their collaborators have identified genes that play key roles ...

Home February 06, 2023
Home
Subscribe Now